Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
- Trade
- Markets
- Copy
- Contests
- News
- 24/7
- Calendar
- Q&A
- Chats
Trending
SYMBOL
LAST
BID
ASK
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6835.40
6835.40
6835.40
6861.30
6834.81
+7.99
+ 0.12%
--
DJI
Dow Jones Industrial Average
48481.79
48481.79
48481.79
48679.14
48478.65
+23.75
+ 0.05%
--
IXIC
NASDAQ Composite Index
23194.63
23194.63
23194.63
23345.56
23186.20
-0.53
0.00%
--
USDX
US Dollar Index
97.820
97.900
97.820
98.070
97.790
-0.130
-0.13%
--
EURUSD
Euro / US Dollar
1.17573
1.17580
1.17573
1.17596
1.17262
+0.00179
+ 0.15%
--
GBPUSD
Pound Sterling / US Dollar
1.33929
1.33937
1.33929
1.34014
1.33546
+0.00222
+ 0.17%
--
XAUUSD
Gold / US Dollar
4318.53
4318.94
4318.53
4350.16
4294.68
+19.14
+ 0.45%
--
WTI
Light Sweet Crude Oil
56.704
56.734
56.704
57.601
56.666
-0.529
-0.92%
--
- All
- Chatrooms
- Groups
- Friends
Connecting
.
.
.
- All
- Russia-Ukraine Conflict
- Middle East Flashpoint
Pliant Therapeutics to lay off 45% of Workforce in Restructuring Move
MT Newswires
Pliant Therapeutics said late Thursday it is laying off around 45% of its workforce in a strategic restructuring targeted at preserving cash reserves while it completes late-stage clinical trials.
Pliant said it expects to complete the restructuring process by the end of Q2, as it focuses on maintaining its late-stage clinical trial execution capabilities.
The company said it expects topline data from its phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis in Q2, and will determine its next steps afterwards.
The company anticipates to recognize about $3.6 million in total for severance and related benefits for employees laid off under the reduction in force, according to a regulatory filing.
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
Copyright © 2025 FastBull Ltd
728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG
Risk Disclosure
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Become a signal provider
Help Center
Dark Mode
Price Up/Down Colors
Log In
Sign Up